Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

101. Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia

Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia Aristada (aripiprazole lauroxil) U.S. Department of Health and Human Services Search FDA Submit search Aristada (aripiprazole lauroxil) Aristada (aripiprazole lauroxil) Company: Alkermes, Inc. Application No.: 207533 Approval Date: October 5, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2015

102. Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes

Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Article Text Midwifery Cohort study Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous

Evidence-Based Nursing (Requires free registration)2015

103. Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia

Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Article Text Electronic pages Causes and risk factors Elevated C reactive protein in adults predicts the later development of late

Evidence-Based Mental Health2015

104. Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia

Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Article Text Psychological interventions Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Jerome Favrod 1

Evidence-Based Mental Health2015

105. Helping people with schizophrenia to quit smoking

Helping people with schizophrenia to quit smoking Helping people with schizophrenia to quit smoking | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Helping people with schizophrenia to quit smoking Article Text Evidence-based case conference Helping people with schizophrenia to quit smoking Free Toshi A Furukawa Statistics from Altmetric.com No Altmetric data available for this article. Clinical case Patient A 38-year-old man. Present illness The patient developed schizophrenia in his mid-20s when he was working as a shop assistant in a busy

Evidence-Based Mental Health2015

106. Metformin to reduce weight gain and metabolic disturbance in schizophrenia

Metformin to reduce weight gain and metabolic disturbance in schizophrenia Metformin to reduce weight gain and metabolic disturbance in schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin to reduce weight gain and metabolic disturbance in schizophrenia Article Text Pharmacological interventions Metformin to reduce weight gain and metabolic disturbance in schizophrenia Guy Faulkner , Mark Duncan Statistics from Altmetric.com No Altmetric data available for this article. ABSTRACT FROM: Mizuno Y, Suzuki T, Nakagawa A, et al

Evidence-Based Mental Health2015

107. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia

Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Article Text Causes and risk factors Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Vishal

Evidence-Based Mental Health2015

108. Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder

Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder REXULTI (brexpiprazole) Tablets U.S. Department of Health and Human Services Search FDA Submit search REXULTI (brexpiprazole) Tablets ENTRESTO Company: Otsuka Pharmaceutical Company, Ltd. Application No.: 205422Orig1s000 and 205422Orig2s000 Approval Date: July 10, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2015

110. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.

Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. BACKGROUND: Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic drugs, however, low-potency antipsychotic drugs are sometimes perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side effects. OBJECTIVES: To review the effects in clinical response (...) of flupenthixol and low-potency antipsychotics for people with schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (July 2010). SELECTION CRITERIA: Randomised controlled trials that compared flupenthixol with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For continuous data, we calculated mean differences (MD) based on a random-effects model

Cochrane2014

111. Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip

Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip %PDF-1.4 %���� 55 0 obj > endobj 76 0 obj >/Filter/FlateDecode/ID[ ]/Index[55 32]/Info 54 0 R/Length 101/Prev 532132/Root 56 0 R/Size 87/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"'�I+� gn�ց� `v�t�$�����T�6AD����I�(10�D�r�� 5��u�p $�G���q��I >stream h�b``f``�b``�`�g@�@���р,& � �@�Ɂ}ú�� � 7-��|*8��`�t���1k sک��| �3�i&��>�'�Vw�*C��0 endstream endobj 56 0 obj

All Wales Medicines Strategy Group2014

112. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Haute Autorite de sante2014

113. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Lurasidone (Latuda - Sunovion Pharmaceuticals (...) Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that lurasidone be listed for the management of the manifestations of schizophrenia if the following clinical criteria are met: 1. Patient has a contraindication to less expensive antipsychotic agents, or 2. Patient has failed a trial of less expensive antipsychotics because of intolerance

Health Technology Assessment (HTA) Database.2014

114. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation CADTH. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Clinical Report. 2014 Authors' conclusions The main reason for the original CDEC recommendation of "Do Not List" was a lack of sufficient evidence to establish the comparative efficacy of lurasidone against other AAPs. In this updated review, no additional RCTs meeting the inclusion

Health Technology Assessment (HTA) Database.2014

115. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions At the submitted price of XXXXXX, lurasidone (XXXXXX per year) is less expensive than aripiprazole ($1,509 to $1,746 per year) and ziprasidone ($1,448 per year). Therefore, lurasidone would

Health Technology Assessment (HTA) Database.2014

116. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. IMPORTANCE: Long-acting injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia-spectrum disorders. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotics has not been assessed. OBJECTIVE: To compare the effectiveness of the second-generation long-acting injectable (...) antipsychotic paliperidone palmitate with the older long-acting injectable antipsychotic haloperidol decanoate. DESIGN, SETTING, AND PARTICIPANTS: Multisite, double-blind, randomized clinical trial conducted from March 2011 to July 2013 at 22 US clinical research sites. Randomized patients (n = 311) were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to be at risk of relapse and likely to benefit from a long-acting injectable antipsychotic. INTERVENTIONS

JAMA2014

117. Horticultural therapy for schizophrenia.

Horticultural therapy for schizophrenia. BACKGROUND: Horticultural therapy is defined as the process of utilising fruits, vegetables, flowers and plants facilitated by a trained therapist or healthcare provider, to achieve specific treatment goals or to simply improve a person's well-being. It can be used for therapy or rehabilitation programs for cognitive, physical, social, emotional, and recreational benefits, thus improving the person's body, mind and spirit. Between 5% to 15% of people (...) with schizophrenia continue to experience symptoms in spite of medication, and may also develop undesirable adverse effects, horticultural therapy may be of value for these people. OBJECTIVES: To evaluate the effects of horticultural therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care or other additional psychosocial interventions. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (Janurary 2013) and supplemented this by contacting relevant

Cochrane2014

118. Aripiprazole (Abilify) - maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole

Aripiprazole (Abilify) - maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole

Scottish Medicines Consortium2014

119. Smoking cessation in patients with schizophrenia

Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smoking cessation in patients with schizophrenia. Lansdale: HAYES, Inc.. Directory Publication. 2014 Authors' conclusions The purpose of smoking cessation therapies (...) is to decrease smoking and smoking-related morbidity and mortality in patients. Interventions for smoking cessation may be pharmacologic and/or psychosocial. This report focuses on smoking cessation therapies in patients with schizophrenia. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Humans; Schizophrenia; Smoking Cessation Language Published English Country of organisation United States English summary An English language summary is available

Health Technology Assessment (HTA) Database.2014

120. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial.

Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. BACKGROUND: Antipsychotic drugs are usually the first line of treatment for schizophrenia; however, many patients refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was effective in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take antipsychotic (...) drugs. METHODS: We did a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. Participants aged 16-65 years with schizophrenia spectrum disorders, who had chosen not to take antipsychotic drugs for psychosis, were randomly assigned (1:1), by a computerised system with permuted block sizes of four or six, to receive cognitive therapy plus treatment as usual, or treatment as usual alone. Randomisation was stratified by study site. Outcome assessors were

Lancet2014